Form 4: ALX Oncology Holdings SVP Sells Shares for Tax Obligations Under 10b5-1 Plan

Shelly Pinto, SVP of Finance and CAO at ALX Oncology Holdings Inc., sold 1,532 shares of common stock to cover tax obligations related to restricted stock unit vesting, executed under a Rule 10b5-1 plan.

Summary

• Shelly Pinto, the Senior Vice President of Finance and Chief Accounting Officer (SVP, FINANCE AND CAO) of ALX Oncology Holdings Inc. (ALXO), reported a transaction.
• On June 30, 2025, Pinto sold 1,532 shares of ALXO common stock.
• The shares were sold at a price of $0.43 per share.
• The sale was conducted to satisfy tax obligations arising from the vesting of restricted stock units.
• This transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Shelly Pinto beneficially owns 88,820 shares of ALXO common stock.

Sentiment

Score: 7

Explanation: The transaction is a routine sale to cover tax obligations from RSU vesting, executed under a Rule 10b5-1 plan. This is a common practice for executives and does not typically reflect a negative outlook on the company's future performance. The insider retains a substantial holding.

Positives

• The sale was for tax obligations related to Restricted Stock Unit (RSU) vesting, a routine and expected event for executives.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a discretionary one based on immediate market views.
• Shelly Pinto retains a significant holding of 88,820 shares of ALXO common stock after the sale.

Negatives

• The transaction represents a reduction of 1,532 shares in Shelly Pinto's direct beneficial ownership.

Future Outlook

No forward-looking statements or guidance are provided in this document.

Management Comments

• The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

Industry Context

This is a routine insider transaction (tax-related sale) common across all industries when restricted stock units vest. It does not provide specific industry context for the oncology sector.

Comparison to Industry Standards

• This is a standard Form 4 filing for a tax-related sale of shares, a common practice for executives across various industries to cover tax liabilities upon the vesting of equity awards.
• The execution of the sale under a Rule 10b5-1 plan aligns with best practices for insider trading compliance, demonstrating a pre-planned, non-discretionary transaction.

Related Party Transactions

• Sale of 1,532 common shares by Shelly Pinto, SVP, Finance and CAO, to satisfy tax obligations related to restricted stock unit vesting.

Stakeholder Impact

• Shareholders: Experience minor dilution from the sale, but the reason (tax obligations under a 10b5-1 plan) is routine and generally not a cause for concern regarding management's confidence.
• Employees, Customers, Suppliers, Creditors: No direct impact mentioned or implied by this specific transaction.

Key Dates

Recommendation

Keywords

ALX Oncology Holdings Inc., ALXO, Shelly Pinto, Form 4, insider trading, stock sale, restricted stock units, RSU, tax obligations, corporate officer, SVP Finance, CAO, Rule 10b5-1